Rexahn Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update

ROCKVILLE, Md., May 04, 2017 (GLOBE NEWSWIRE) — Rexahn Pharmaceuticals, Inc. (NYSE MKT:<a href=””>RNN</a>), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced financial results for the first quarter ended March 31, 2017 and provided an update on the Company’s clinical development programs.